44 results on '"Lindegaard, H M"'
Search Results
2. POS0052 FIVE-YEAR FOLLOW-UP OF A 2-YEAR MRI TREAT-TO-TARGET STRATEGY ON RADIOGRAPHIC DAMAGE PROGRESSION IN RHEUMATOID ARTHRITIS PATIENTS IN CLINICAL REMISSION - THE IMAGINE-MORE STUDY
3. POS0010 PROTEOMIC LANDSCAPE OF SYNOVIAL TISSUE IN RHEUMATOID ARTHRITIS AND DETERMINANTS OF SYNOVIAL HISTOLOGICAL PATHOTYPES
4. Prediction of treatment response to adalimumab: a double-blind placebo-controlled study of circulating microRNA in patients with early rheumatoid arthritis
5. CERTOLIZUMAB-PEGOL, ABATACEPT, TOCILIZUMAB OR ACTIVE CONVENTIONALTHERAPY IN EARLY RHEUMATOID ARTHRITIS: CLINICAL AND RADIOGRAPHIC 48-WEEKS RESULTS OF THE INVESTIGATOR-INITIATED RANDOMIZED NORD-STARTRIAL
6. Galectin‐3 is Persistently Increased in Early Rheumatoid Arthritis (RA) and Associates with Anti‐CCP Seropositivity and MRI Bone Lesions, While Early Fibrosis Markers Correlate with Disease Activity
7. OP0058 CERTOLIZUMAB-PEGOL, ABATACEPT, TOCILIZUMAB OR ACTIVE CONVENTIONAL THERAPY IN EARLY RHEUMATOID ARTHRITIS: CLINICAL AND RADIOGRAPHIC 48-WEEKS RESULTS OF THE INVESTIGATOR-INITIATED RANDOMIZED NORD-STAR TRIAL
8. POS0550 LONG TERM EFFICACY OF A 2-YEAR MRI TREAT-TO-TARGET STRATEGY ON DISEASE ACTIVITY, MRI INFLAMMATION AND PHYSICAL FUNCTION IN RHEUMATOID ARTHRITIS PATIENTS IN CLINICAL REMISSION: FIVE YEAR FOLLOW-UP OF THE IMAGINE RA-COHORT
9. AB1354 ULTRASOUND JOINT EXAMINATION BY AN AUTOMATED SYSTEM VERSUS BY A RHEUMATOLOGIST – FROM A PATIENT PERSPECTIVE
10. POS0377 FIBROCYTES IN EARLY AND LONGSTANDING RHEUMATOID ARTHRITIS: A 6-MONTH TRIAL WITH REPEATED SYNOVIAL BIOPSY, IMAGING, AND LUNG FUNCTION TEST
11. THE IMPACT OF AN ULTRASOUND ATLAS FOR SCORING SALIVARY GLANDS IN PRIMARY SJOGREN'S SYNDROME: A RELIABILITY EXERCISE
12. CHARACTERISTICS OF PRIMARY SJOGREN'S SYNDROME INCLUDING ULTRASOUND FINDINGS OF THE SALIVARY GLANDS, ESSDAI AND ESSPRI
13. FRI0019 MRI INFLAMMATION, DISEASE ACTIVITY AND FUNCTIONAL IMPAIRMENT ARE MORE EFFECTIVELY REDUCED BY ESCALATION TO BIOLOGICS COMPARED TO CSDMARD-ESCALATION IN RHEUMATOID ARTHRITIS PATIENTS IN CLINICAL REMISSION FOLLOWING A TREAT-TO-TARGET STRATEGY: SECONDARY ANALYSES OF THE IMAGINE-RA TRIAL
14. SAT0130 TREAT-TO-TARGET STRATEGY OF >8.000 PATIENTS WITH EARLY RHEUMATOID ARTHRITIS: DOES SMOKING AFFECT ACHIEVEMENT OF REMISSION ON METHOTREXATE AND TIME TO START OF FIRST BIOLOGIC? RESULTS FROM THE NATIONWIDE DANISH DANBIO REGISTRY
15. OP0312 THE IMPACT OF AN ULTRASOUND ATLAS FOR SCORING SALIVARY GLANDS IN PRIMARY SJÖGREN’S SYNDROME: A RELIABILITY EXERCISE
16. SAT0233 CHARACTERISTICS OF PRIMARY SJÖGREN’S SYNDROME INCLUDING ULTRASOUND FINDINGS OF THE SALIVARY GLANDS, ESSDAI AND ESSPRI
17. AB0209 PREDICTORS OF ACHIEVING STRINGENT REMISSION IN PATIENTS WITH ESTABLISHED RHEUMATOID ARTHRITIS IN CLINICAL REMISSION FOLLOWING A TREAT-TO-TARGET STRATEGY
18. Do changes in prescription practice in patients with rheumatoid arthritis treated with biological agents affect treatment response and adherence to therapy? Results from the nationwide Danish DANBIO Registry
19. Circulating Surfactant Protein D is Decreased in Early Rheumatoid Arthritis: A 1-year Prospective Study
20. MAGNETIC RESONANCE IMAGING TENOSYNOVITIS AND OSTEITIS ARE INDEPENDENT PREDICTORS OF RADIOGRAPHIC AND MRI DAMAGE PROGRESSION IN RHEUMATOID ARTHRITIS PATIENTS IN CLINICAL REMISSION
21. Low-cost, low-field dedicated extremity magnetic resonance imaging in early rheumatoid arthritis: a 1-year follow-up study
22. Safety, feasibility and tolerability of performing consecutive minimal invasive ultrasound-guided synovial biopsy procedures on the same wrist in a prospective rheumatoid arthritis study
23. FIVE-YEAR FOLLOW-UP OF A 2-YEAR MRI TREAT-TO-TARGET STRATEGY ON RADIOGRAPHIC DAMAGE PROGRESSION IN RHEUMATOID ARTHRITIS PATIENTS IN CLINICAL REMISSION - THE IMAGINEMORE STUDY.
24. Three months’ clinical outcomes from a nationwide non-medical switch from originator to biosimilar infliximab in patients with in flammatory arthritis:Results from the DANBIO registry
25. Three months’ clinical outcomes from a nationwide non-medical switch from originator to biosimilar infliximab in patients with inflammatory arthritis. Results from the DANBIO registry
26. Prediction of treatment response to adalimumab:a double-blind placebo-controlled study of circulating microRNA in patients with early rheumatoid arthritis
27. Fast Infusion of TOCILIZUMAB in Rheumatoid Arthritis is Well Tolerated
28. Predictive values of anti-cyclic citrullinated peptide antibodies and rheumatoid factor in relation to serological aspects of the ACR/EULAR 2010 classification criteria for rheumatoid arthritis.
29. Serious Adverse Events Associated with use Biological Agents for the Treatment of Rheumatic Diseases:Network Meta-Analysis from a National Guideline Panel
30. Prediction of treatment response to adalimumab: a double-blind placebo-controlled study of circulating microRNA in patients with early rheumatoid arthritis
31. PROTEOMIC LANDSCAPE OF SYNOVIAL TISSUE IN RHEUMATOID ARTHRITIS AND DETERMINANTS OF SYNOVIAL HISTOLOGICAL PATHOTYPES.
32. Impact of different infliximab dose regimens on treatment response and drug survival in 462 patients with psoriatic arthritis: results from the nationwide registries DANBIO and ICEBIO
33. THU0050 Circulating Lung Surfactant Protein D (SP-D) Differs Between Rheumatoid Arthritis (RA) Patients According to Anti-Citrullinated Protein Antibody (Anti-CCP) and IGM-Rheumafactor (IGM-RF) Status
34. THU0197 Presence of Antibodies to Adalimumab and Infliximab in Patients with Rheumatoid Arthritis in Clinical Remission
35. SAT0016 Microrna Expression Profiles as Biomarkers for Prediction of Treatment Response to Adalimumab in Patients with Early Rheumatoid Arthritis
36. FRI0113 Rheumatoid arthritis and eosinophilia: the risk of lymphoproliferative malignancies and solid cancers. a study based on the copenhagen primary care differential count (copdiff) database
37. THU0212 Improved Remission Rates Acquired by Adding Adalimumab to Methotrexate and Intraarticular Glucocorticoid Cannot be Maintained after Withdrawal of Adalimumab. A 2-Year Investigator Initiated Randomised, Controlled Study on Early Rheumatoid Arthritis
38. Circadian pattern and the effect of standardized physical exercise on procollagen IIA N-peptide (PIIANP) in rheumatoid arthritis at different stages and in healthy individuals
39. Circulating Surfactant Protein D is Decreased in Early Rheumatoid Arthritis: A 1-year Prospective Study
40. Do rheumatoid arthritis patients in clinical practice benefit from switching from infliximab to a second tumor necrosis factor alpha inhibitor?
41. Circadian pattern and the effect of standardized physical exercise on procollagen IIA N-peptide (PIIANP) in rheumatoid arthritis at different stages and in healthy individuals.
42. Wrist inflammation as assessed by magnetic resonance imaging is associated with patient-reported physical impairment, global disease activity and pain in early rheumatoid arthritis: long-term results from two randomized controlled trials
43. MRI inflammation, disease activity and functional impairment are more effectively reduced by escalation to biologics compared to CSDMARD-escalation in rheumatoid arthritis patients in clinical remission following a treat-to-target strategy: secondary analyses of the imagine-ra trial
44. Doubling the single-dose infusion rate of tocilizumab in rheumatoid arthritis is safe and efficacious.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.